Propanc Biopharma, Inc. Sample Contracts
PREFUNDED COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, iNC.Security Agreement • April 3rd, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations
THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to 10,445,482 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Notwithstanding anything herein to the contrary, all share numbers under this Warrant shall be subject to adjustment for reverse and forward stock splits and the like.
COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, INC.Common Stock Purchase Warrant • April 2nd, 2025 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [●], 20[●] (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receiv
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 14th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June __, 2019 between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 3rd, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 30, 2020, between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 15th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 3, 2019, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and CROWN BRIDGE PARTNERS, LLC, a New York limited liability company, with its address at 1173a 2nd Avenue, Suite 126, New York, NY 10065 (the “Buyer”).
UNDERWRITING AGREEMENT between PROPANC BIOPHARMA, INC. AndUnderwriting Agreement • May 30th, 2025 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
The undersigned, Propanc Biopharma, Inc. , a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with D. Boral Capital LLC, (hereinafter referred to as “you,” “D. Boral Capital,” or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) to issue and sell an aggregate of [*] shares (“Firm Shares”) of the Company’s common stock, $0.001 par value per share, (“Common Stock”), and at the election of the Representative, up to an additional [*] share(s) of Common Stock (the “Option Shares” and together with the Firm Shares, the “Shares”). The Firm Shares and the Option Shares, are collectively referred to as the “Public Securities.” The offering and sale of the Public Securities contemplated by this Agreement are referred to herein as the “Offering.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 3rd, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2020, between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 21st, 2025 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 15, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite 202, Reno, NV 89502 (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 21st, 2025 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Virginia
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 25, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Alexandria VA 22314 (the “Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 26th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 20, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND L.P., a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented, or otherwise modified from time to time, the “Purchase Agreement”).
10% PROMISSORY NOTEConvertible Security Agreement • May 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS IS A 10% PROMISSORY NOTE of Propanc Biopharma, Inc. (the “Company”), a Delaware Corporation, having its principal place of business at 302. 6 Butler Street, Camberwell, VIC 3124, Australia (this “Note”), which represents a duly authorized and validly issued debt of the Company.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 7th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This Registration Rights AGREEMENT (the “Agreement”), dated as of December 1, 2016 (the “Execution Date”), is entered into by and between Propanc Health Group Corporation, a Delaware corporation with its principal executive office at 302, 6 Butler Street Camberwell, VIC 3124 Australia (the “Company”), and GHS Investments LLC, a Nevada limited liability company, with offices at 200 Stonehinge Lane, Suite 3, Carle Place, NY 11514. (the “Investor”).
5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE september 13, 2017Convertible Security Agreement • September 16th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • New York
THIS 5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of PROPANC HEALTH GROUP CORPORATION, a Delaware corporation, (the “Company”), having its principal place of business at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia, designated as its 5% Original Issue Discount Senior Secured Convertible Debenture due September 13, 2017 (the “Debenture”).
COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, INC.Security Agreement • September 9th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the $550,000.00 convertible promissory note to the Holder (as defined below) of even date) (the “Note”), Auctus Fund, LLC, a Delaware limited liability company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to 225,000 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated August 30, 2019, by and among the Company
SECURITY AGREEMENTSecurity Agreement • September 29th, 2015 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of September 24, 2015 (this “Agreement”), is among Propanc Health Group Corp., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holder of the Company’s promissory note in the original aggregate principal amount of $1,200,000 (the “Debenture”) signatory hereto, its endorsees, transferees and assigns (collectively, the “Secured Parties”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 14th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
EQUITY PURCHASE AGREEMENT BY AND BETWEEN PROPANC HEALTH GROUP CORPORATION AND SOUTHRIDGE PARTNERS II LP Dated July __, 2014Equity Purchase Agreement • September 22nd, 2014 • Propanc Health Group Corp • Pharmaceutical preparations • New York
THIS EQUITY PURCHASE AGREEMENT entered into as of the ___ day of February, 2014 (this "AGREEMENT"), by and between SOUTHRIDGE PARTNERS II LP, a Delaware limited partnership ("INVESTOR"), and PROPANC HEALTH GROUP CORPORATION, a Delaware corporation (the "COMPANY").
EQUITY FINANCING AGREEMENTEquity Financing Agreement • December 7th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This EQUITY FINANCING AGREEMENT (the “Agreement”), dated as of December 1, 2016 (the “Execution Date”), is entered into by and between Propanc Health Group Corporation, a Delaware corporation with its principal executive office at 302, 6 Butler Street Camberwell, VIC 3124 Australia (the “Company”), and GHS Investments LLC, a Nevada limited liability company, with offices at 200 Stonehinge Lane, Suite 3, Carle Place, NY 11514. (the “Investor”).
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • February 25th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Kansas
THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of February 25, 2019 (the “Execution Date”), by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 22nd, 2014 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This Registration Rights Agreement ("Agreement"), dated July __, 2014, is made by and between PROPANC HEALTH GROUP CORPORATION, a Delaware corporation ("Company"), and SOUTHRIDGE PARTNERS II LP a Delaware limited partnership (the "Investor").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 3, 2022 between Propanc Biopharma, Inc. a Delaware corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (“Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2024 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 20, 2024, by and between Propanc Biopharma, Inc., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124, Australia (the “Company”), and 104 LLC, a Nevada limited liability company, with its address at 21520 Yorba Linda Blvd., Suite G PMB 335, Yorba Linda, CA 92887 (the “Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 25th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Kansas
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 25, 2019 (the “Execution Date”), is entered into by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SECURITY AGREEMENTSecurity Agreement • November 3rd, 2015 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of October __, 2015 (this “Agreement”), is among Propanc Health Group Corp., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holder of the Company’s 5% Original Issue Discount Senior Secured Convertible Debenture due twelve (12) months following its issuance, in the original aggregate principal amount of $4,400,000 (the “Debenture”) signatory hereto, its endorsees, transferees and assigns (collectively, the “Secured Parties”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 30th, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”), dated as of December 23, 2020 and effective as of December 23, 2020 (the “Effective Date”), is made by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and Josef Zelinger (“Indemnitee”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • July 26th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Common Stock Purchase Agreement is entered into as of July 20, 2023 (this “Agreement”), by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND L.P., a Delaware limited partnership (the “Investor”). The Company and Investor may be referred to herein as each a “Party” and, collectively, the “Parties”.
COMMON STOCK PURCHASE WARRANT PROPANC HEALTH GROUP CORP.Common Stock Purchase Warrant • November 3rd, 2015 • Propanc Health Group Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Delafield Investments Limited or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the four (4) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Health Group Corp., a Delaware corporation (the “Company”), up to 26,190,476 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CANCELLATION AGREEMENTCancellation Agreement • August 18th, 2021 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS CANCELLATION AGREEMENT (this “Agreement”), is entered into effective as of August 12, 2021, by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”) and Dr. Julian Kenyon,
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • November 1st, 2022 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this“Agreement”) dated October 26, 2022, is made effective as of July 1, 2022 (the “Effective Date”) by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and James Nathanielsz (“Executive”). The Company and Executive sometimes are referred to herein collectively as the “Parties” and each individually as a “Party”. This Agreement is intended to and hereby amends and restates in its entirety that certain Employment Agreement between the Parties entered into on February 25, 2015, and as amended on April 14, 2016, September 25, 2017 and May 14, 2019.
DEBT EXCHANGE AGREEMENTDebt Exchange Agreement • March 31st, 2025 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Florida
This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of February 05, 2025, is entered into by and among Propanc Biopharma, Inc a Delaware corporation (the “Company”) and Notestar Pty Ltd (the “Creditor” and together with the Company, the “Parties” and each, a “Party”).
ContractCollateralized Secured Promissory Note • April 13th, 2015 • Propanc Health Group Corp • Pharmaceutical preparations
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. LENDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
ContractNote Agreement • September 22nd, 2014 • Propanc Health Group Corp • Pharmaceutical preparations
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. LENDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 14th, 2025 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2025, is by and among Propanc Biopharma, Inc., a Delaware corporation with offices located at 302, 6 Butler Street, Camberwell, VIC, 3124, Australia (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
Employment AgreementEmployment Agreement • March 25th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • Delaware
This Employment Agreement (the "Agreement") is made and entered into as of February 25th, 2015, by and between James Nathanielsz (the "Executive") and ProPanc Health Group Corporation, a Delaware Corporation (the "Company"), (collectively the “Parties”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • May 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Common Stock Purchase Agreement (the “Agreement”) is entered into as of November 3, 2022, by and between PROPANC BIOPHARMA INC., a Delaware corporation (the “Company”), and COVENTRY ENTERPRISES, LLC, a Delaware limited liability company (the “Investor”). The Company and Investor may be referred to herein as each a ‘‘Party” and collectively, the “Parties”.